You are here

Approvals, Launches, and New Indications

Fifth agency nod since drug’s 2006 launch
Wireless controller allows patients to expand device at home
Results are available in about an hour
Product consists of autologous cells on bioresorbable collagen membrane
Extended-release tablet contains empagliflozin and metformin
Prescription device provides insulin dosing recommendations
New ovarian cancer indication joins several previous cancer approvals
Post-marketing study links treatment to reduced risk of cardiovascular death
Kinase inhibitor treats CML and Ph+ AML